LNSR

+ Watchlist + Portfolio

LENSAR, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.72
52-Week Range: $4.95 – $12.96
Market Cap: $103.69M
P/E (TTM): 42.20
EPS (TTM): 0.20
Dividend Yield: —

Advanced Metrics

Price/Book: 6.95
PEG Ratio: —
Return on Equity: 357.30%
Return on Assets: -18.66%
Gross Margin: 48.34%
Operating Margin: 12.94%
Profit Margin: 57.57%
Current Ratio: 2.39
Debt/Equity: 0.08
Total Debt: $2.38M
Free Cash Flow: $-24.39M
Revenue Growth: 18.40%
Earnings Growth: —
Enterprise Value: $105.74M

LNSR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$35.36M	$42.16M	$53.49M	$58.44M
Cost of Revenue	$15.40M	$21.06M	$27.64M	$31.31M
Gross Profit	$19.95M	$21.11M	$25.85M	$27.12M
Research & Development	$11.81M	$6.14M	$5.33M	$5.62M
Selling, General & Admin	$27.17M	$26.10M	$26.49M	$45.16M
Operating Expenses	$40.13M	$33.34M	$32.79M	$51.70M
Operating Income	-$20.18M	-$12.23M	-$6.94M	-$24.58M
EBITDA	-$16.77M	-$8.71M	-$3.00M	-$20.08M
Pretax Income	-$19.91M	-$14.38M	-$31.40M	-$34.28M
Net Income	-$19.91M	-$14.38M	-$31.40M	-$34.28M
Diluted EPS	-1.96	-1.31	-2.73	-2.87
Diluted Shares	10.16M	10.97M	11.52M	11.96M

LNSR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$14.67M	$20.62M	$16.26M	$12.97M
Receivables	$6.24M	$4.32M	$6.48M	$6.67M
Inventory	$11.74M	$15.69M	$11.43M	$21.52M
Current Assets	$33.72M	$46.44M	$41.98M	$46.77M
Total Assets	$55.84M	$69.58M	$66.30M	$71.43M
Current Liabilities	$11.42M	$11.63M	$15.00M	$40.57M
Total Debt	$2.80M	$2.31M	$2.61M	$2.73M
Total Liabilities	$13.86M	$36.16M	$61.44M	$97.45M
Retained Earnings	-$97.51M	-$111.89M	-$143.29M	-$177.57M
Shareholders' Equity	$41.98M	$33.43M	$4.86M	-$26.02M
Working Capital	$22.30M	$34.81M	$26.98M	$6.20M

LNSR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$14.86M	-$9.66M	-$2.27M	-$14.83M
Capital Expenditure	-$115.00K	-$236.00K	-$156.00K	-$83.00K
Free Cash Flow	-$14.97M	-$9.89M	-$2.43M	-$14.91M
Depreciation & Amortisation	$3.41M	$3.52M	$3.93M	$4.50M
Stock-Based Compensation	$6.61M	$5.54M	$2.67M	$3.14M
Investing Cash Flow	-$115.00K	-$4.16M	-$2.16M	$1.28M
Financing Cash Flow	-$1.99M	$19.76M	$78.00K	$10.26M
Net Change in Cash	-$16.96M	$5.95M	-$4.36M	-$3.29M

LNSR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$14.16M	$13.94M	$14.32M	$16.02M	$13.43M
Cost of Revenue	$7.03M	$6.91M	$8.28M	$9.09M	$7.05M
Gross Profit	$7.13M	$7.02M	$6.04M	$6.94M	$6.38M
Research & Development	$1.53M	$1.43M	$1.37M	$1.30M	$1.39M
Selling, General & Admin	$11.15M	$11.66M	$12.02M	$10.33M	$2.53M
Operating Expenses	$12.91M	$13.31M	$13.62M	$11.86M	$4.14M
Operating Income	-$5.79M	-$6.29M	-$7.58M	-$4.92M	$2.24M
EBITDA	-$4.71M	-$5.19M	-$6.42M	-$3.75M	$3.37M
Pretax Income	-$27.34M	-$1.76M	-$3.71M	-$1.46M	$36.33M
Net Income	-$27.34M	-$1.76M	-$3.71M	-$1.46M	$36.33M
Diluted EPS	-2.32	-0.15	-0.31	-0.12	0.00
Diluted Shares	11.77M	11.94M	12.04M	12.07M	15.42M

LNSR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$19.55M	$7.15M	$7.64M	$12.97M	$12.49M
Receivables	$7.24M	$5.32M	$6.19M	$6.67M	$5.18M
Inventory	$15.32M	$19.24M	$20.60M	$21.52M	$23.10M
Current Assets	$49.19M	$45.87M	$44.43M	$46.77M	$42.40M
Total Assets	$72.96M	$70.41M	$70.20M	$71.43M	$66.22M
Current Liabilities	$27.17M	$30.09M	$35.73M	$40.57M	$17.80M
Total Debt	$2.47M	$2.33M	$2.88M	$2.73M	$2.57M
Total Liabilities	$95.10M	$93.47M	$96.11M	$97.45M	$55.43M
Retained Earnings	-$170.64M	-$172.40M	-$176.12M	-$177.57M	-$141.24M
Shareholders' Equity	-$22.14M	-$23.05M	-$25.91M	-$26.02M	$10.79M
Working Capital	$22.01M	$15.78M	$8.70M	$6.20M	$24.60M

LNSR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.94M	-$5.00M	-$3.51M	$618.00K	-$4.27M
Capital Expenditure	-$6.00K	-$77.00K	—	—	—
Free Cash Flow	-$6.94M	-$5.08M	-$3.51M	$618.00K	-$4.27M
Depreciation & Amortisation	$1.08M	$1.09M	$1.16M	$1.17M	$1.13M
Stock-Based Compensation	$654.00K	$766.00K	$850.00K	$873.00K	$690.00K
Investing Cash Flow	$531.00K	-$7.49M	$4.00M	$4.25M	$4.00M
Financing Cash Flow	$9.69M	$93.00K	$0.00	$474.00K	-$209.00K
Net Change in Cash	$3.28M	-$12.40M	$487.00K	$5.34M	-$480.00K

Market Snapshot

About

LENSAR, Inc. is a commercial-stage medical device company focused on advanced femtosecond laser technology for cataract surgery and refractive procedures. The company's ALLY Adaptive Cataract Treatment System uses augmented reality and advanced imaging to enhance surgical precision and outcomes. LENSAR's technology aims to improve the standard of care in cataract surgery by providing surgeons with enhanced visualization and precision. The company markets its systems to ophthalmologists and ambulatory surgery centers.